• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 1st December 2015

OHE at ISPOR Europe: Milan 2015

A summary of OHE’s presentations and contributions at ISPOR Europe, Milan 2015. The ISPOR 18th Annual European Congress was held in Milan, Italy, 7-11 November 2015. OHE’s Director of Research, Nancy Devlin, participated in the Third Plenary and a Workshop…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
ISPOR-2015-2

A summary of OHE’s presentations and contributions at ISPOR Europe, Milan 2015.

The ISPOR 18th Annual European Congress was held in Milan, Italy, 7-11 November 2015. OHE’s Director of Research, Nancy Devlin, participated in the Third Plenary and a Workshop and presented two posters, whilst Director Adrian Towse had the honour of presenting ISPOR’s 2015 Donabedian Award to Tony Culyer. This post contains presentations and posters relating to Adrian and Nancy’s contributions to the ISPOR conference.

Presentation of the Donebedian Award to Tony Culyer

The ISPOR Avedis Donabedian Outcomes Research Lifetime Achievement Award acknowledges individuals who have made a major contribution to the improvement of health outcomes. The 2015 Award was to Tony Culyer. Adrian made the presentation speech, covering briefly Tony’s contribution to: health economics thinking; teaching and advising; academic institutions; and public policy making. This included comments on: his role in reorganising NHS R&D, and in setting up NICE; his theoretical contribution to extra-welfarism, and to the understanding of what is meant by equity and need; and his thinking on deliberative decision making. 

Access Adrian’s speech here.

To view Tony Culyer’s response, click here.

Towse Donebedian Award to Tony Culyer from Office of Health Economics

Plenary session: Recommendations from the ISPOR Multi-Criteria Decision Analysis Emerging Good Practice Task Force and Remaining Controversies

In this session, the panellists discussed the good practice recommendations of the ISPOR MCDA Task Force Report.  As one of the Task Force Co-chairs, Nancy responded to comments from Brett Hauber and Mónica Duarte Oliveira.  Nancy’s presentation slides are below. 

Response from Taskforce from Office of Health Economics

Those of the other panellists (Maarten Ijzerman, Kevin Marsh, Brett Hauber and Mónica Duarte Oliveira) can be accessed here.

Workshop: Utilities in HTA: Challenges for Theory and Practice Now and in the Future.

Nancy, along with Mike Drummond and Jenny Berg, ran a Workshop to discuss methodological and practical challenges regarding generation and use of utility data in HTA. Nancy presented on “Theoretical foundations and challenges” arguing that the researchers’ choices made about which methods to use in eliciting and modelling stated preference data can have an important impact on the utilities used in HTA – and QALY estimates and therefore on resource allocation. In her presentation, Nancy examined the extent to which the theory of extra welfarism, which underpins QALY-based HTA systems, provides guidance on which methods to use in establishing utilities. Nancy’s presentation slides are below. 

Theoretical Foundations and Challenges from Office of Health Economics

Those of the Mike Drummond and Jenny Berg can be accessed here.

Two poster presentations

Nancy also presented two posters, one with OHE’s Health of Outcomes Mike Herdman. The abstracts are set out below. 

Poster presentation: Health-related Quality of Life (HRQoL) Benefits of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer (MCRPC): an In-depth Analysis of EQ-5D Data from the Prevail Trial.

Devlin N, Herdman M, Pavesi M, Phung D, Naidoo S, Beer TM, Tombal B, Loriot Y, Ivanescu C, Parli T, Balk M, Holmstrom S.

OHE’s Nancy Devlin and Mike Herdman presented a poster based on their analysis of EQ-5D data from a clinical trial of enzalutamide, examining the effects on health-related quality of life (HRQoL) in the PREVAIL trial in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC). Patients received oral enzalutamide 160 mg/day (n=872) or placebo (n=845). EQ-5D Index and EQ-5D visual analogue scale (VAS) scores were evaluated at baseline, Week 13 and every 12 weeks until drug discontinuation. Changes on individual dimensions were assessed, and Paretian Classification of Health Change (PCHC) – a method developed by Nancy to examine dimension-level changes in patients’ self-reported health (Devlin, Parkin and Browne 2010) and time-to-event analyses conducted. Results showed that with enzalutamide, EQ-Index and VAS scores declined more slowly versus placebo and time to diverge from full health was prolonged.  Average decline in EQ-Index (-0.042 versus -0.070, p<0.0001) and EQ-VAS (-1.3 versus -4.4, p<0.0001) was significantly smaller with enzalutamide. There were significant (p<0.05) between-group differences in favour of enzalutamide in Pain/Discomfort dimension through to Week 37, Anxiety/Depression at Week 13 and Usual Activities at Week 25 but no significant differences for Mobility and Self-care. PCHC analysis showed a greater proportion of enzalutamide patients reporting improvement versus placebo at Weeks 13, 25 and 49 (all p<0.05) and at Week 37 (p=0.0512). Enzalutamide was superior (p<0.001) to placebo for time to diverge from full health and time to first deterioration on Pain/Discomfort and Anxiety/Depression dimensions. 

The study concluded that, compared with placebo, in addition to delaying HRQoL deterioration, enzalutamide had beneficial effects on several HRQoL domains, including Pain/discomfort, and the proportion of patients in full health. 

HRQoL effects of enzalutamide from Office of Health Economics

Poster presentation: Qualitative Interviews to Provide In-depth Understanding of the Impact of Non-small Cell Lung Cancer (NSCLC) and its Treatment on of the Lives of Patients and their Families/Caregivers.

Mulatero C, Lal R, Jewitt K, Tolley C, Wells J, Arbuckle R, Lloyd A, Brazier J, Devlin N.

The aim of this study was to better understand the impact of advanced NSCLC and its treatment on the quality of life and lived experience of patients, in order to inform the optimal design and inclusion of outcome assessments in clinical trials. Face-to-face, qualitative, semi-structured interviews were conducted with 20 UK participants with advanced NSCLC. Interviews explored participants’ experiences of NSCLC and the treatment and care they received. Open-ended questioning, to facilitate spontaneous reporting, was followed by focused questions to further investigate important themes. Verbatim transcripts were analyzed using a data-driven, thematic analysis. Participants experienced considerable burden from symptoms and treatment-related side effects (e.g. breathlessness, nausea), which left them unable to participate in activities of daily living such as housework, shopping or going outside. However, participants reported that it was the emotional impact on them and their families (e.g. worry, sadness and frustration) that had the biggest negative impact on their lives. Almost all participants were highly satisfied with their treatment and care, but time lost to receiving and recovering from treatment was a commonly reported negative impact. Efficiency, communication and practical and emotional support were aspects of care valued most by participants. The majority of participants (11/16 asked) said they would prioritise improving quality of life over extending life. The study concluded that advanced NSCLC impacts many domains of participants’ lives. This study demonstrates that emotional impact and time taken undergoing treatment may be undervalued by the commonly employed HRQoL metrics in clinical trials. Future clinical trials of new lung cancer treatments should include assessment of these outcome measures and tools to satisfactorily capture all factors deemed important by patients should be developed to fully reflect impact of new treatments on HRQoL on patients.

Impact of NSCLC and its Treatment on Patients from Office of Health Economics
 

Related News

Group 11119
  • News
  • February 2023

Applications open for MSc Fellowship Programme 2023

Read more
Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • July 2022

OHE is Leading Research to Develop an EQ-5D ‘Bolt-on’ for Hearing

Read more
MicrosoftTeams-image-6_0
  • News
  • June 2022

OHE’s 60th Anniversary Party – Celebrating Our Achievements and Looking Forward

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!